文献速递腹部技术与安全USCT

动态超声造影分析在小(≤20 mm)实性胰腺病变鉴别诊断中的附加价值

Added Value of Dynamic Contrast-Enhanced Ultrasound Analysis for Differential Diagnosis of Small (≤20 mm) Solid Pancreatic Lesions.
PubMed 文献 · Ultrasound Med Biol · 2025-01-02

本回顾性研究纳入76例经病理证实的小(≤20 mm)实性胰腺病变患者,术前一周行B型超声和超声造影检查,利用VueBox软件生成时间-强度曲线并计算定量参数。结果显示,DCE-US定量参数联合鉴别小恶性与良性实性胰腺病变的AUC为0.919,敏感度87.2%、特异度86.5%,优于增强CT的敏感度74.4%和特异度75.7%。结论认为DCE-US分析为小恶性实性胰腺病变的术前鉴别诊断提供了附加价值。

要点

  • 小恶性实性胰腺病变在DCE-US上表现为动脉期增强更早更低、静脉期下降更快、曲线下面积减小。
  • 较低的峰值增强比和较高的下降时间比在小恶性实性胰腺病变中更常见(p < 0.05)。
  • DCE-US定量参数联合鉴别小恶性与良性实性胰腺病变的AUC为0.919,敏感度87.2%、特异度86.5%,优于增强CT。

核心结论

  • DCE-US分析为小恶性实性胰腺病变的术前鉴别诊断提供了附加价值。

研究设计与样本

  • 回顾性研究,纳入76例经活检或手术切除组织病理学证实的小(≤20 mm)实性胰腺病变患者,共76个病灶,使用ACUSON Sequoia超声系统配备5C1 MHz凸阵探头,造影剂为SonoVue 1.5 ml,采用VueBox软件生成时间-强度曲线并计算定量参数。

关键影像表现/征象

  • B型超声上多数恶性(37/39,94.9%)和良性(30/37,81.1%)小实性胰腺病变为低回声、边界不清、形态不规则(p > 0.05)。
  • 超声造影动脉期多数病变(59/76,77.6%)与周围胰腺实质呈等增强。
  • 静脉期82.1%(32/39)恶性病变和35.1%(13/37)良性病变出现廓清,静脉期和延迟期呈低增强(p > 0.05)。
  • 与良性病变相比,小恶性病变的时间-强度曲线显示动脉期增强更早、更低,静脉期下降更快,曲线下面积减小。

诊断标准与关键数值

  • DCE-US显著定量参数联合鉴别小恶性与良性实性胰腺病变的AUC为0.919,敏感度87.2%,特异度86.5%。
  • 增强CT鉴别小恶性与良性实性胰腺病变的敏感度74.4%,特异度75.7%。
  • 较低的峰值增强比和较高的下降时间比在小恶性实性胰腺病变中更常见(p < 0.05)。

临床应用与阅片要点

  • 术前DCE-US定量分析可用于小(≤20 mm)实性胰腺病变的良恶性鉴别,其联合参数诊断效能优于增强CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the added value of dynamic contrast-enhanced ultrasound (DCE-US) analysis in pre-operative differential diagnosis of small (≤20 mm) solid pancreatic lesions (SPLs).

METHODS: In this retrospective study, patients with biopsy or surgerical resection and histopathologically confirmed small (≤20 mm) SPLs were included. One wk before biopsy/surgery, pre-operative B-mode ultrasound and contrast-enhanced ultrasound were performed. An ultrasonic system (ACUSON Sequoia, Siemens Medical Solutions, PA, USA) equipped with a 5C1 MHz convex array transducer was utilized. A dose of 1.5 ml SonoVue (Bracco, Italy) was injected as the contrast agent. Time-intensity curves were generated using VueBox software (Bracco) and various DCE-US quantitative parameters were subsequently calculated after curve fitting. Univariate and multivariate logistic regression analysis were utilized.

RESULTS: From August 2020 to November 2023, a total of 76 patients (31 males and 45 females; mean age: 61.9 ± 10.5 y) with 76 small (≤20 mm) SPLs were included. Mean size of the lesions was 16.4 ± 0.4 mm (range: 7-20 mm). Final diagnosis included 37 benign and 39 malignant small SPLs. On B-mode ultrasound, the majority of malignant (37/39, 94.9%) and benign SPLs (30/37, 81.1%) were hypo-echoic lesions with ill-defined borders and irregular shapes (p > 0.05). During the arterial phase of contrast-enhanced ultrasound, most SPLs (59/76, 77.6%) exhibited iso-enhancement when compared with surrounding pancreatic parenchyma. Subsequently, 82.1% (32/39) of malignant SPLs and 35.1% (13/37) of benign SPLs demonstrated wash-out in the venous phase and showed hypo-enhancement in venous and late phases (p > 0.05). Compared with benign SPLs, the time-intensity curves of small malignant SPLs revealed earlier and lower enhancement in the arterial phase, and a faster decline during the venous phase with a decreased area under the curve. Among the quantitative parameters, a lower peak enhancement ratio and higher fall time ratio were more common in small malignant SPLs (p < 0.05). For DCE-US analysis, the combined areas under the curve of significant quantitative parameters was 0.919, with 87.2% sensitivity and 86.5% specificity when differentiating between small malignant and benign SPLs. This result was better than contrast-enhanced computed tomography, which has a sensitivity of 74.4% and a specificity of 75.7%.

CONCLUSION: DCE-US analysis provides added value for the pre-operative differential diagnosis of small malignant SPLs.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Lu XY, Cao JY, Chen S, et al. Added Value of Dynamic Contrast-Enhanced Ultrasound Analysis for Differential Diagnosis of Small (≤20 mm) Solid Pancreatic Lesions. Ultrasound Med Biol. 2025. PMID: 39753466. doi:10.1016/j.ultrasmedbio.2024.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。